Published: Mar 02, 2021
New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development
New Directors will provide significant guidance as Tenax is poised to advance its two leading drug candidates into late-stage clinical testing
Transformational step as Tenax strengthens its positioning as a leading specialty pharmaceutical company focused on cardio-pulmonary therapeutics
a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need, today announced the appointment of four new members to its board of directors: June Almenoff, MD, PhD, Michael Davidson, MD, Delcan Doogan, MD, and Stuart Rich, MD.